Dr. Reddy's Laboratories (RDY) to Release Earnings on Tuesday

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) is scheduled to be announcing its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.86 per share for the quarter.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its earnings results on Wednesday, January 31st. The company reported $0.99 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.11. Dr. Reddy's Laboratories had a return on equity of 20.97% and a net margin of 19.26%. The firm had revenue of $867.00 million for the quarter, compared to the consensus estimate of $827.81 million. On average, analysts expect Dr. Reddy's Laboratories to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Dr. Reddy's Laboratories Stock Performance

Shares of RDY traded down $0.95 during mid-day trading on Tuesday, reaching $73.47. The company had a trading volume of 181,990 shares, compared to its average volume of 195,432. Dr. Reddy's Laboratories has a 52-week low of $53.12 and a 52-week high of $77.72. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $12.26 billion, a P/E ratio of 19.46, a PEG ratio of 1.86 and a beta of 0.58. The stock has a 50 day moving average of $74.15 and a two-hundred day moving average of $70.54.

Wall Street Analyst Weigh In

RDY has been the subject of a number of research analyst reports. Jefferies Financial Group cut Dr. Reddy's Laboratories from a "buy" rating to an "underperform" rating in a report on Thursday, January 11th. StockNews.com raised Dr. Reddy's Laboratories from a "buy" rating to a "strong-buy" rating in a report on Friday, April 5th. Finally, Barclays increased their price target on Dr. Reddy's Laboratories from $75.00 to $80.00 and gave the company an "overweight" rating in a report on Monday, January 29th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Dr. Reddy's Laboratories has an average rating of "Hold" and a consensus target price of $80.00.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.